Dr Shonit Punwani appointed BRC Director of Clinical Imaging
The BRC is delighted to announce the appointment of Dr Shonit Punwani as BRC Director of Clinical Imaging, under its cross-cutting theme Healthcare Engineering & Imaging (HE&I).
This new leadership position will build on and encourage links between the clinical themes to enable ambitions cross-cutting activities such as large-scale imaging trials, novel imaging biomarkers and cutting edge analysis. The position will also establish the necessary infrastructure system to allow researchers from across UCL to access the state-of-the-art imaging devices at UCLH without disrupting the clinical workflow.
This work is integral to the progress of the HE&I theme, led by Professor Seb Ourselin and directly affiliated with the UCL Institute of Healthcare Engineering, which is also led by Professor Ourselin and aims to provide access to engineering and imaging equipment and expertise, enabling effective, rapid and robust clinical translation and application of innovative HE&I solutions to target key clinical problems.
Dr Punwani: said "I am very excited to be given this opportunity. I have always been keen to help establish processes that can remove obstacles and provide the structure necessary to take novel imaging methods from concept to the clinic. There is a wealth of imaging expertise within the UCLH BRC and I hope that during this appointment I can help to establish an environment where ideas can flourish, be shared between groups and rapidly translate to patient benefit."
Professor Ourselin, HE&I Theme Director said: “I’m thrilled that Shonit has accepted the position. The Director of Clinical Imaging is fundamental to the long term strategies of both the BRC and the HE&I theme in supporting the collaboration of clinicians and engineers across UCL and UCLH.”
Professor Bryan Williams, BRC Director, said: “I am delighted that Shonit has been appointed to this key role in the BRC. I see advanced imaging as being centre stage in experimental medicine in evaluating disease progression and effectiveness of new interventions and Shonit is ideally placed to help drive this forward.”